Pre-made Adalimumab benchmark antibody ( Whole mAb, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-009
Pre-Made Adalimumab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Adalimumab, sold under the brand name Humira, among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Use is generally only recommended in people who have not responded to other treatments. It is administered by injection under the skin.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Adalimumab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||6cr1:HL/4nyl:AB:CD:EF:HL|
|99% SI Structure||3wd5:HL|
|95-98% SI Structure||None|
|Companies||Abbvie;MedImmune;180 Life Sciences|
|Conditions Approved||Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma|
|Conditions Active||Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis|
|Conditions Discontinued||Interstitial cystitis|
|Development Tech||CAT Phage Display|